Skip to content
Homepage
Author:
Pluristyx, Inc.
Posted Date:
July 6, 2026
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
Pluristyx, Inc.
July 6, 2026
Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership
Pluristyx, Inc.
June 16, 2026
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
Pluristyx, Inc.
May 1, 2026
Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology
Pluristyx, Inc.
April 7, 2026
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
Pluristyx, Inc.
March 17, 2026
Pluristyx and Solesis Launch First-of-its-Kind PluriForm™-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
Pluristyx, Inc.
February 8, 2026
